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The relative clinical efficacy and systemic effects of different inhaled corticosteroids is controversial. To obtain 
further information on this matter, the authors have performed meta-analyses of seven trials comparing fluticasone 
propionate (FP) with budesonide (Bud), and seven trials comparing FP with beclomethasone dipropionate (BDP) 
for the treatment of asthma of all severities in adult and paediatric patients. In all cases, the drugs were compared 
at clinically equivalent doses, i.e. FP was given at half (or less) the microgram dose. The total number of patients was 
1980 (1000 treated with FP 200-800,~~g day- ’ and 980 with Bud 400-1600pg day- ‘); and 1584 patients in the 
second analysis (780 treated with FP 200-1000 lug day- ’ and 804 with BDP 400-2000 pg day - ‘). FP significantly 
improved mean morning peak expiratory flow rate (PEFR) compared with Bud, with an overall difference of 
+ll lmin-’ . Analysis of serum cortisols showed no differences between FP and Bud treatment at low doses, but at 
higher dosages, and overall, significant differences in favour of FP were observed. In the second meta-analysis, no 
significant differences in PEFR were observed between FP and BDP in any of the seven individual studies or in the 
pooled analysis. Analysis of serum cortisols showed a similar trend to the previous analysis, however, no overall 
difference in serum cortisol results were seen between FP and BDP. In conclusion, the pooled analysis shows that FP 
at half the dose (or less) is more effective than Bud and as effective as BDP in improving PEFR; in addition, these 
improvements were achieved with a reduction in cortisol suppression compared with BUD and with no greater 
degree of cortisol suppression compared with BDP. This demonstrates, in patients with asthma, that FP has an 
improved efficacy to safety ratio compared with older inhaled corticosteroids. 
RESPIR. MED. (1998) 92, 95-104 
Introduction 
The efficacy of inhaled corticosteroids for the treatment of 
asthma is well documented, with national and international 
treatment guidelines recommending their use as first-line 
therapy for all except mild asthma (1,2). These guidelines 
use a step-wise approach to therapy with increases in 
the dose of inhaled corticosteroids recommended if 
disease control is considered inadequate. In practice, many 
physicians establish the optimum maintenance dose by 
initiating therapy at a high dose, which is then reduced once 
symptoms have been controlled, a practice now endorsed 
by the new British Asthma Guidelines (3). 
However, the use of high doses of inhaled corticosteroids 
in greater numbers of patients and for longer periods has 
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led to concern over the potential for systemic adverse 
effects, most notably suppression of the hypothalamic 
pituitary adrenal (HPA) axis, effects on bone metabolism 
and effects on growth of children (4-6). These systemic 
effects are due to a combination of the swaIlowed and 
inhaled portion of the drug. 
Fluticasone propionate (FP) is a new generation, topical 
glucocorticosteroid for the treatment of asthma in adults 
and children. In vitro data have shown FP to be more 
potent at a given microgram dose than either budesonide 
(Bud) or beclomethasone dipropionate (BDP) (7). Further- 
more, FP exhibits minimal oral systemic availability com- 
pared to Bud (< 1 vs 1 l%, respectively) (8,ll) or BDP 
(estimated at 20%). This is most likely due to a combination 
of poor gastrointestinal absorption and almost complete 
first-pass metabolic inactivation (9-l 1). FP therefore 
appears to have the potential for a greater therapeutic index 
than Bud or BDP. Although many studies have been 
performed comparing FP with Bud and BDP, controversy 
exists as to the relative clinical efficacy and safety of the 
different inhaled steroids. 
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TAESLE 2. Summary of BUD trials: confidence intervals for treatment differences in final week mean 
morning peak flow 
Trial 
Average difference Lower 95% Upper 95% 
(FP-BUD) confidence limit confidence limit P-value 
Williams (1995) 6.7 0.5 13.0 0.036 
Langdon & Thompson (1994) 1.8 - 18.0 21.6 0.8 
Connolly et al. (1995) 6.3 - 9.5 22.1 0.4 
Langdon & Capsey (1994) 20.8 6.6 34.9 0.005 
Backman et al. (1996) 8.5 - 3.4 20.4 0.16 
Steinmetz & Trautmann (1996) 16.5 6.1 26.4 0.001 
Ringdal et al. (1996) 15.3 6.6 24.1 <O.OOl 
Pooled 10.9 7.1 14.7 <O.OOl 
TABLE 3. Summary of BUD trials: confidence intervals for treatment ratio of final visit plasma 
cortisollbaseline plasma cortisol 
Trial 
Average ratio Lower 95% Upper 95% 
(FP/BUD) confidence limit confidence limit P-value 
Langdon & Thompson (1994) 0.95 0.80 1.14 0.6 
Connolly et al. (1995) 0.99 0.86 1.14 0.9 
Langdon & Capsey (1994) 1.00 0.89 1.13 0.9 
Backman et al. (1996) 1.30 1.14 1.48 <O.OOl 
Ringdal et al. (1996) 1.12 1.02 1.24 0.014 
Pooled 1.09 1.03 1.15 0.005 
To evaluate further the efficacy and safety of FP relative 
to Bud and BDP in patients with asthma, we have per- 
formed a meta-analysis of all studies (as of December 1995) 
in adults and children where FP was used at half the 
microgram dose (or less) of Bud or BDP and morning peak 
expiratory flow rate (PEFR) was an outcome measure. In 
vitro and initial clinical studies have indicated a 2: 1 potency 
ratio of FP to Bud and BDP (11-13) and FP is recom- 
mended for use at half the dose of Bud and BDP in national 
and international guidelines (3). 
Methods 
SELECTION OF STUDIES 
The meta-analysis included seven studies evaluating the 
safety and efficacy of FP vs Bud (13-19) and seven studies 
vs BDP (12,20&25). Criteria for inclusion were studies of FP 
vs Bud or BDP in which FP was used at half or less of the 
dose of Bud or BDP, in which daily morning peak expir- 
atory flow rate (PEFR) was an outcome measure and which 
were reported by December 1995. One further study com- 
paring FP vs BDP in China was known to have completed 
patient entry, but the data were not reported or available. 
The objective of the analysis was to evaluate all the data 
available to support or refute the hypothesis that FP at half 
the dose (or less) is as effective as Bud and BDP when used 
to treat patients with asthma. Therefore, studies comparing 
the drugs in healthy volunteers or at equal doses were not 
included 
EFFICACY 
In all trials, mean morning PEFR was recorded daily by the 
subjects on a diary card during both the run-in phase and 
the treatment phase. Measurements recorded on the 7 days 
immediately prior to administration of the first dose of 
study medication were combined and divided by the 
number of days for which data were available for that 7-day 
period to obtain a baseline measurement. 
To calculate the mean morning PEFR for the treatment 
phase, the end of treatment was determined from the 
protocol, and the last week was nominally described as 
ending 3 days before the last day of the protocol. This 
ensured that missing values towards the end of the study, 
often due to administrative reasons, did not result in 
substantial missing data. Three days was chosen arbitrarily 
as the minimum necessary, whilst maintaining as long a 
period of treatment exposure as possible. Morning PEFR 
values recorded on this day and the previous 6 days were 
then pooled and divided by the number of days for which 
data were available. This value was then used as the mean 
morning PEFR at the end of therapy. It was necessary to 
use this method to determine mean morning PEFR as it 
was found that many subjects did not complete their diaries 
in full for their final week of treatment. Furthermore, in 
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TABLE 5. Summary of BDP trials: confidence intervals for treatment differences in final week mean 
morning peak flow 
Trial 
Average difference Lower 95% Upper 95% 
(FP-BDP) confidence limit confidence limit P-value 
Dahlet al (1993) 2.1 +8.9 13.1 0.7 
Leblanc et al. (1994) 3.2 - 6.4 12.7 0.5 
Gustafsson et al. (1993) 5.2 - 2.3 12.6 0.2 
Pauwels et al. (1995) 5.9 - 6.0 17.9 0.3 
Lundback et al. (1993) 0.7 - 9.3 10.7 0.9 
Bootsma et al. (1995) 8.6 - 23.3 40.5 0.6 
Barnes et al. (1993) - 5.4 - 24.4 13.6 0.6 
Pooled 3.2 - 0.9 7.4 0.13 
TABLE 6. Summary of BDP Trials: confidence intervals for treatment ratio of final visit plasma 
cortisol/baseline plasma cortisol 
Trial 
Average ratio Lower 95% 
(FPIBDP) confidence limit 
Upper 95% 
confidence limit P-value 
Dahl et al. (1993) 0.99 0.90 1.09 0.051 
Leblanc et al. (1994) 1.13 1.03 1.23 0.012 
Gustafsson et al. (1993) 0‘99 0.91 1.08 0.9 
Pauwels et al. (1995) 0.99 0.88 1.10 0.8 
Lundback et al. (1993) 0.98 0.91 1.06 0.7 
Bootsma et al. (1995) 1.21 1.00 1.46 0.06 
Barnes et al. (1993) 1.25 1.02 1.54 0.030 
Pooled 1.03 0.99 1.07 0.13 
several subjects, morning PEFR values were recorded after 
the end of the treatment period. Therefore, this enabled the 
mean difference in improvement in morning PEFR on 
therapy between FP and Bud or BDP to be calculated in a 
standard way for each trial. 
For each patient, the time to 10% improvement was 
determined as the day at which the diary card morning 
PEFR reached 10% or more of the mean baseline value. 
Exacerbations of asthma were collected from the diary 
cards, and the overall percentage of patients in each trial 
with exacerbations was calculated. 
SYSTEMIC ACTIVITY 
Morning serum cortisol levels (8810 am) were used as a 
measure of systemic activity. Serum cortisols were 
measured in 12 of the 14 trials included in this meta- 
analysis. For each of these studies, the ratio between the 
mean serum cortisol level (nmol l- ‘) at baseline (a day 
prior to taking treatment) and at the end of therapy (last 
day of treatment) was determined for both study drugs and 
the mean difference between cortisol ratios on FP and Bud 
or BDP was compared. 
STATISTICAL ANALYSIS 
To perform the meta-analysis on the mean morning PEFR, 
each separate trial was analysed with all patients included 
and using a common model involving centre, baseline and 
treatment factors [SA@ Proc GLM (PC Version 6.08)]. 
Similarly, in the meta-analysis for the plasma cortisol, 
each separate trial was analysed using the logarithm of the 
‘end-treatment’ plasma cortisol as the response variable 
with centre, logged baseline and treatment factors included 
in the model. Results are given as ratios following back 
transformation. 
As the analysis includes all worldwide studies performed 
at a ratio of at least 1:2, a fixed-effect model was used for 
the meta-analysis. 
A pooled weighted mean of all the separate estimates of 
the treatment differences from each individual trial was 
calculated using the inverse variance from each trial as 
weights. 
The common variance estimate of the pooled treatment 
difference was computed from the inverse sum of the square 
root of the above weights. This pooled variance was then 
used to calculate the confidence limits of the pooled mean 
treatment difference (ratio). (26). 
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FIG. 1. Difference with 95% confidence interval in mean improvement in morning peak expiratory flow rate (PEFR) for 
fluticasone propionate (FP) and budesonide (Bud). MDI, metered-dose inhaler. 
No evidence was found for any heterogeneity among the 
estimates of morning PEFR or cortisol. 
Results 
DEMOGRAPHICS 
Studies included in this analysis encompassed all severities 
of asthma in adult and paediatric patients, except for 
patients on regular oral steroids. Seven studies compared 
doses of FP 200-8OOpg day- ’ with Bud 400~16OO~g 
day - ’ administered via powder and metered-dose inhaler 
delivery systems. A total of 1980 patients recorded efficacy 
data in these trials, 1000 of whom were treated with FP and 
980 with Bud. Individual study details are summarized in 
Tables l-3. Seven studies compared FP 200-1000 pg day - ’ 
with BDP 400-2000,~~g day-‘. A total of 1584 patients 
recorded efficacy data in these trials, 780 of whom were 
treated with FP and 804 with BDP. Individual study details 
are summarised in Tables 4-6. Two studies involved 
children, one with Bud and one with BDP. The remaining 
12 studies were carried out in adults, covering all asthma 
severities up to moderate severe, and employed a variety of 
powder and aerosol delivery devices. All studies were 
controlled, with eight being blinded and six open-label. 
EFFICACY 
FP vs BUD 
In all studies comparing FP at half the dose (or less) with 
Bud, mean improvements in morning PEFR on therapy 
from baseline favoured FP, attaining statistical significance 
in four of the seven trials (Fig. 1). The pooled analysis 
across all seven studies also significantly favoured FP, 
with a mean difference in improvement in morning PEFR 
on therapy between FP and Bud of + 11 1 min- ’ (95% 
confidence interval +7 to + 15). 
FP vs BDP 
There were no statistically significant differences in 
improvement in morning PEFR between FP at half the 
dose compared with BDP in any of the seven trials (Fig. 2). 
The pooled analysis showed a non-significant trend in 
favour of FP with a mean difference in improvement 
in morning PEFR on therapy between FP and BDP of 
+3 1 min-’ (950/ o confidence interval - 0.9 to +7). 
SAFETY 
FP vs BUD 
Mean changes in serum cortisol levels on therapy were 
determined in five studies comparing FP at half the dose (or 
less) with Bud. As would be expected, no significant inter- 
group differences in serum cortisols were detected at low 
doses. However, significant differences in favour of FP were 
apparent at higher dose levels (FP 2 500 pg day ~ 1 and Bud 
2 1200 pg day - ‘) (Fig. 3). The pooled analysis across all 
five studies also revealed a significant difference in co&sol 
ratios favouring FP (ratio = 1.09 nmol 1~ ‘; 95% confidence 
interval 1.03-1.15). 
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FP vs BDP however, the pooled analysis across all seven studies 
showed no significant difference in cortisol ratios 
Mean changes in serum cortisol levels did not differ signifi- 
cantly between treatments in the studies comparing FP at 
half the dose with BDP below 1OOOpg day-’ (Fig. 4). At 
higher doses, a difference in favour of FP was apparent, 
(ratio= 1.03 nmol l- i; 95% confidence interval 0.99-1.07). 
Exacerbations of asthma were also collected for patients 
in these studies. These results showed that exacerbations 
occurred for between 4 and 10% of patients. No apparent 
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FIG. 4. Difference with 95% confidence interval in the ratio of mean serum cortisol level at baseline and at the end of 
therapy between fluticasone propionate (FP) and beclomethason dipropionate (BDP). MDI, metered-dose inhaler. 
differences were seen for the percentage of patients suffer- 
ing from an exacerbation, irrespective of their treatment, 
suggesting a similar effect on asthma control. 
Discussion 
FP KS BUD 
The results of this meta-analysis indicate that FP at half the 
dose (or less) is more effective for the treatment of asthma 
than Bud, irrespective of delivery system, as indicated by 
improvements in morning PEFR. This analysis also rein- 
forces the findings of some individual studies (13-19) which 
have been used to claim a 2:l potency ratio compared with 
Bud. The pooled analysis in mean changes in serum cortisol 
levels favoured FP over Bud, although, as might be antici- 
pated, significant differences between these two cortico- 
steroids were only seen at higher dose levels. Limitations of 
the analysis focus on the fact that some of the studies were 
open-label, because of difficulty in obtaining placebo 
devices for Bud. However, it is noteworthy that the double 
blind, double-dummy study significantly favoured FP, both 
in terms of efficacy and safety, and reflected the pooled 
analysis result. 
The results of this meta-analysis, therefore, contrast with 
some reports which have suggested that FP has greater 
systemic activity than Bud in normal volunteers (27729) 
highlighting the difficulties with extrapolating findings from 
normal subjects to patients with clinical disease. There are a 
number of possible explanations for these different findings. 
Hypothalamic-pituitary-adrenal (HPA) axis function may 
be less affected by doses of inhaled corticosteroid in patients 
with normal lifestyle functioning than those in rested 
normal volunteers. The pathophysiological pulmonary 
changes associated with asthma may result in clinically 
relevant differences in the pattern of drug distribution and 
absorption in the lung between asthmatic patients and 
normal subjects, and such differences could explain 
alterations in the degree or rate of systemic drug absorption 
(30). Finally, in patients with asthma, differences in the 
respiratory fraction between delivery devices may not 
account for the variation in efficacy and systemic activity 
seen in normal subjects (31). 
FP KS BDP 
Comparisons between FP at half the dose and BDP showed 
that both treatments were equally as effective in terms of 
changes in PEFR. Mean changes in serum cortisol levels 
showed that at doses 275Opg day- ’ (and also at one of 
the lower doses), differences between FP and BDP were just 
statistically significant. However, no overall difference was 
observed between these two drugs in the pooled analysis. 
Summary 
While results of the individual studies generally revealed no 
significant differences in plasma cortisol levels between FP 
YS Bud, and also FP vs BDP, at low doses, differences in 
favour of FP at higher dose levels were detected. This may 
have important implications for patient management, as 
the major concern with currently available drugs of this 
class is the apparent increased risk of systemic effects, such 
as suppression of the HPA axis and effects on bone 
metabolism, at high doses (4-6). 
The meta-analyses demonstrate that FP across a dose 
range of 200-8OOpg day -I is more effective than Bud 
400-16OOpg day-’ and across a dose range of 200-1000 pug 
day ~ ’ as effective as BDP 400&2OOO~g day ~ ’ for the 
treatment of asthma. FP is also less likely to suppress mean 
morning serum cortisol levels than Bud, particularly/ 
moderate to severe asthma where higher dosages of inhaled 
corticosteroids are required. Therefore, the results of this 
meta-analysis confirm that FP at half the clinically recom- 
mended dose of Bud or BDP is an effective treatment 
option for asthma of all severities in both adult and 
paediatric patients. Therefore, FP provides the potential for 
an improved therapeutic efficacy to safety ratio compared 
with Bud and BDP. 
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